
|Videos|January 26, 2022
Assessing the Future of Inclisiran in Clinical, Pharmacy Settings
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol management.
During the interview, Lepor discussed projections for the use of inclisiran in clinical and pharmacy settings.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
2
FDA Approves Dolutegravirfor HIV Treatment in Newborns
3
FDA Clears First Continuous Glucose-Ketone Monitor
4
There Is No Such Thing as a Healthy Tan: Sunburn, SPF, and Skin Cancer
5

































































































